| http://www.w3.org/ns/prov#value | - These risks, including the success of our existing collaborations, the marketing and sales efforts for LUCENTIS and CIMZIA, our ability to enter into additional arrangements, the size and timing of expenditures, our ability to remain in compliance with or renegotiate the requirements of our loan agreements, the timing of clinical trials and other events, changes in our collaborative relationships
|
